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Abstract
The European Union offers opportunities for high-level of funding of collaborative European 
research. Calls are regularly published: after the end of the FP7 funding programme the new 
round of Horizon 2020 calls started in 2015. Several topics are relevant to inflammatory bowel 
disease (IBD) challenges, including chronic disease management, biomarker discovery and new 
treatments developments. The aim of this Viewpoint article is to describe the new Horizon 2020 
instrument and the project submission procedures, and to highlight these through the description 
of tips and tricks, taking advantage of four examples of successful projects in the field of IBD: the 
SADEL, IBD-BIOM, IBD Character and BIOCYCLE projects.
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1. Introduction
In the context of the new round of Horizon 2020 calls for proposals 
and the launch for the first time of an open-access European Union 
(EU) Project Forum at the ECCO’16 Congress in Amsterdam, this 
seems an opportune time to provide an insight into the funding 
mechanism for Horizon 2020 and the opportunities that it offers the 
inflammatory bowel disease (IBD) community.
This Viewpoint Article was initiated by asking the different pro-
ject coordinators involved in the EU Project Forum to inform JCC 
readers of their experiences in gaining EU funding and to briefly 
describe their projects. The aim is to equip the reader with the 
knowledge required to submit persuasive applications for EU fund-
ing and to report individual experiences gained with respect to the 
SADEL, IBD-BIOM, IBD Character and BIOCYCLE projects.
2. What is Horizon 2020?
Horizon 2020 is the financial instrument for research and innova-
tion in the EU. It will run from 2014 to 2020 with a budget of nearly 
€80 billion.
Horizon 2020 is the successor to the Seventh Framework 
Programme for Research (FP7). It is a single programme bring-
ing together FP7, Euratom, the Competitiveness and Innovation 
Programme (CIP) and the European Institute of Innovation and 
Technology (EIT). In comparison with FP7, Horizon 2020 provides 
major simplification through a single set of rules.
By means of this programme, the EU will finance interdiscipli-
nary projects that effectively address the economic and social chal-
lenges faced by the EU. The programme aims to secure Europe’s 
global competitiveness and is part of the drive to create new jobs 
and growth in Europe by:
•	 Coupling research to innovation – from research to retail, cover-
ing all forms of innovation;
•	 Stimulating further innovation, through the introduction of ‘close-
to-market actions’, e.g. prototyping, testing and demonstrating;
•	 Focusing on societal challenges in the EU, e.g. with respect to 
health, clean energy and transport;
•	 Achieving greater involvement of small and medium-sized enter-
prises (SMEs).1
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Horizon 2020 is built around three pillars:
1. Support for ‘Excellent Science’ – including grants for individual 
researchers from the European Research Council (ERC) and 
Marie Skłodowska-Curie fellowships (formerly known as Marie 
Curie fellowships);
2. Support for ‘Industrial Leadership’ – including grants for SMEs 
and indirect finance for companies through the European Invest-
ment Bank and other financial intermediaries;
3. Support for research to tackle ‘Societal Challenges’.2
The European Commission has published details of Horizon 
2020 reviewers on the Participant Portal; first and last names, 
nationality, field of expertise and last employer’s name are available 
for 23 reviewers.
3. What are the upcoming opportunities in 
health research?
3.1. Societal challenges – personalized medicine
The Horizon 2020 Societal Challenges Programme reflects the policy 
priorities of the Europe 2020 strategy and addresses major concerns 
shared by people across Europe and beyond. The concerns of citizens 
and EU policy objectives (regarding climate, environment, energy, 
transport etc.) cannot be addressed and achieved without innovation 
and multidisciplinary collaborations.
Societal Challenges funding will be focused on the following calls:
•	 Health, demographic change and well-being;
•	 Food security, sustainable agriculture and forestry, marine and 
maritime and inland water research, and the bioeconomy;
•	 Secure, clean and efficient energy;
•	 Smart, green and integrated transport;
•	 Climate action, environment, resource efficiency and raw materi-
als;
•	 Europe in a changing world: inclusive, innovative and reflective 
societies;
•	 Secure societies – protecting the freedom and security of Europe 
and its citizens.2
On October 13, 2015, the EU Commission launched new calls 
under the ‘Societal Challenges’ pillar. One call dedicated to personal-
ized medicine,3 with a budget of €659 million, offers many funding 
opportunities. The European Commission has stated that this call 
aims to ‘boost European industry and the so-called silver economy 
by investing in strategies for earlier and more effective prevention, 
diagnosis and treatments, and to help Europe address the ageing 
population and chronic disease burden’.4
3.2. The EU health strategy ‘Together for Health’
The new EU Health Programme came into force in March 2014. 
With a budget of €449.4 million, this programme is the main 
European Commission instrument for implementation of the EU 
health strategy, the goal of which is to complement, support and 
add value to the policies of Member States in order to improve the 
health of EU citizens and reduce health inequalities. The programme 
aims to:
•	 Promote health, prevent diseases and foster supportive environ-
ments for healthy lifestyles, taking into account the ‘health in all 
policies’ principle;
•	 Protect EU citizens from serious cross-border health threats;
•	 Contribute to innovative, efficient and sustainable health sys-
tems;
•	 Facilitate access to better and safer healthcare for EU citizens.5
The Health Programme is managed on behalf of the European 
Commission by the Consumers, Health and Food Executive Agency.6 
Any upcoming call will be published on their website.
3.3. The Innovative Medicines Initiative
The Innovative Medicines Initiative7 (IMI) is a public–private partner-
ship between the EU and the European Federation of Pharmaceutical 
Industries and Associations.8 It aims to create better conditions for 
biopharmaceutical innovation in Europe and accelerate the develop-
ment of better and safer medicines for patients. Through its unique 
and innovative funding scheme, IMI supports research projects in 
the areas of safety and efficacy, knowledge management and educa-
tion and training.9 The research activities supported under the IMI 
are open to all research actors, provided that the activities are per-
formed within Europe.
The IMI launched its sixth call for proposals relating to IMI2 in 
October 2015. Applicant consortia are invited to submit a proposal 
for each of the listed topics that is relevant to them. The scientific 
goals and work packages have already been described for all topics. 
Each proposal should address all aspects of the topic to which the 
proposal relates. The size and composition of each consortium should 
be adapted to reflect the scientific goals and the expected objectives.
4. Tips – help in preparation/submission of a 
project
4.1. National contact points
Horizon 2020 is divided into a range of work programmes and fund-
ing is based on competitive calls. Consortia of researchers (including 
industry) can respond to these calls.
The network of National Contact Points (NCPs) is the main 
structure through which guidance, practical information and assis-
tance are provided on all aspects of participation in Horizon 2020. 
NCPs are national structures established and financed by govern-
ments of the 28 EU member states and the states associated with the 
framework programme. Each area of Horizon 2020 has an NCP that 
can be contacted for more information.
The NCP systems vary from one country to another, from highly 
centralized to decentralized networks, and involve a number of very 
different actors, from ministries to universities etc. It is not the role 
of the NCP to assist in the development of written proposals. They 
can assess whether eligibility criteria have been met, but are unable 
to advise on the likely success of a proposal.
4.2. Steps in submission and submission 
procedures
The competition for funding of proposals relating to Horizon 2020 
is tough. The guidance below provides an introduction to Horizon 
2020 and explains the main steps to be followed when answering a 
call for proposals.
Note that there are two submission procedures for calls within 
Horizon 2020.
•	 The one-stage submission scheme;
•	 The two-stage submission scheme.
The one-stage submission scheme requires one full project pro-
posal to be sent before the stated deadline.
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The two-stage submission procedure allows a consortium to sub-
mit a project abstract focusing on the scientific aspects, the project’s 
goals and the impacts. The abstract will then be reviewed and the 
consortium will be invited to send a full proposal if it successfully 
passes this first evaluation.
4.3. Proposal preparation
Various documents are relevant to preparation of a proposal. First, 
all Horizon 2020 calls are published on the Participant Portal10 of 
the European Commission. Selecting the appropriate call and rel-
evant project partners is an essential first step when preparing a 
project. The section ‘How to participate’ on the Participant Portal 
proposes a number of manuals that can guide you through the pro-
cedure. The H2020 Online Manual describes all the steps that need 
to be followed, the Reference Documents propose various templates, 
evaluation forms and guidance notes, and the Financial Viability 
Self-Check tool assists in simulating the viability check of your 
organization.11
A proposal always consists of two main parts:11
•	 The Technical Annex, a document that presents, in as clear and 
concise a manner as possible, all activities, actions and tasks that 
the partners are committed to undertaking in order to fulfil the 
scientific and research objectives stipulated in the contract;
•	 The Administrative Forms, which contain the administrative and 
organizational information for the project as well as an abstract 
and the budget.
It is crucial to respect the format as well as all the components 
of a proposal, which are equally important, and it must be remem-
bered that clarity is a key prerequisite if a proposal is to be success-
ful. Evaluators are also looking for a balance between partners with 
regard to responsibilities and funding.
It is important not to lose sight of the anticipated impact of the 
proposed project. A proposal that describes research objectives and 
methods extremely well has little chance of success if the project 
management structure is not clearly elaborated and convincing, or if 
the exploitation planning is insufficiently described.11
4.4. Proposal submission and evaluation
The H2020 Online Manual provides detailed step-by-step guidance 
on how to submit a proposal electronically. Submission should be 
made online. It must be ensured that the proposal complies with all 
formal requirements. Some NCPs offer to review proposals. If this 
opportunity is offered, get in touch with your NCP early. Even if 
proposals can be submitted in any official language of the EU, sub-
mission of the proposal in English is recommended.
Remember that call deadlines are absolute and must be 
respected. A proposal will be rejected if it is sent even 1 minute 
too late. Note that it is possible to submit a proposal several times 
as documents can be revised and continually enhanced up to the 
deadline. Each newly submitted version will overwrite previous 
versions, but once the deadline has passed, no further correction 
is possible.
After the submission, each proposal is evaluated individually by 
independent experts, the evaluators. It might be useful to consult 
the ‘Guidance for evaluators of Horizon 2020 proposals’,12 which 
answers the most frequently asked questions about Horizon 2020. 
All proposals with a positive evaluation are ranked and will be 
funded according to their position in the ranking and the available 




The main goal of the SADEL (Scaffolds for Alternative DELivery) 
project is to develop the first generation of oral biotherapeutics 
for IBDs.
Within the European Commission’s FP7, a consortium of nine 
partners from six different European countries started collaborat-
ing on SADEL in 2012. Taking advantage of the Nanofitin protein 
scaffold, the SADEL project aims to develop a blocking protein 
therapeutic deliverable orally for the treatment of IBD. The clini-
cally validated target chosen is tumour necrosis factor-α (TNF-α), a 
cytokine considered a key regulator of immune cells and involved in 
systemic inflammation.
Objectives of this project are:
•	 Better targeting of the inflammation site in the gut via oral 
administration;
•	 Decreasing systemic exposure and related side effects and reduc-
ing immunogenicity;
•	 Providing an efficient, safe and affordable drug in a format that 
increases patient comfort and treatment compliance.
In vivo evaluation based on rectal administration was performed 
as preliminary screening before oral administration. The results were 
beyond the consortium’s expectations, as several non-optimized 
Nanofitins reached a level of efficacy similar to the positive com-
mercial control in the gold standard evaluation animal model. Such 
efficacy was confirmed orally in a curative model, without any for-
mulation optimization. The manufacturing process was translated to 
pilot scale, and the manufacturing yield has been increased by nearly 
50-fold, which is extremely promising for industrialization.
The expected final outcome of the project is preparation of the 
data package for a first-in-man administration. Clinical development 
of the lead compound following the end of the 5-year SADEL project 
has already been covered by an agreement with a European indus-
trial partner, Ferring Pharmaceuticals.
5.2. Experience and advice on proposal preparation
Any application for an EU project must address the topic cited in the 
call and be geared towards delivery of the desired outputs through 
an approach that is both ambitious and demonstrates a significant 
likelihood of success. The call under which the SADEL project was 
initiated was both broad and specific, asking for the development 
of non-antibody biologics for targeted therapies. This description 
was 100% in line with Affilogic’s activities, but we also felt that 
we needed to submit a proposal that would optimally exploit our 
non-antibody technology. One major difference between antibodies 
and non-antibody biologics was expected to be the latter’s poten-
tial for non-intravenous administration. Bearing in mind that opting 
for a non-validated target in an orphan indication would have been 
extremely risky, we were very careful in deciding where to place the 
focus for innovation, and selected the route of administration as our 
primary difference. The target is well known, the models are avail-
able and the indication for oral administration is obvious. IBD is 
indeed a most demanding indication, and by addressing it from the 
intestinal side and being agnostic about the local or systemic effect, 
we doubled our chances of eliciting an anti-inflammatory effect. 
Once the main challenge had been decided, it was all about increas-
ing the chances of success.
One non-technical aspect of great importance in maximizing the 
likelihood of success is very careful choice of consortium partners. 
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Key competencies and other aspects relevant to achievement of the 
project’s aims must be identified and taken into account. If the project 
entails commercialization of a product or health-related programmes 
involving drug development, it is important to have around the table a 
stakeholder able to develop and commercialize the outputs. An indus-
trial partner should be involved in the consortium during the prepara-
tion phase or, as in the case of SADEL, immediately after the beginning 
of the project in order to help manage the project and improve the 
target product profile. For SADEL, we have the chance of benefiting 
from the significant experience of Ferring Pharmaceuticals in IBD.
It is possible to work with a consultant to set up the consor-
tium (as was done for SADEL) or to screen on the internet and 
contact persons directly. You should not hesitate to initiate contacts 
even with key opinion leaders, renowned researchers or clinicians, 
because if the project is really interesting it will attract their interest. 
A  number of partner search services are provided directly by the 
European Commission (e.g. via the H2020 Participant Portal) and 
can be used as a starting point.
Capability is one key criterion in selecting consortium partners. 
Willingness, alignment with personal objectives and motivation are 
also very important but are extremely difficult to assess beforehand. 
In order to assemble the best team possible, we relied heavily on 
personal networks, personal meetings and experience in former col-
laborative projects. Size matters: obviously, the smaller the group, 
the easier it is to manage. Insofar as it was possible, we avoided 
duplication of capabilities while maximizing complementary compe-
tencies. This approach helps in achieving a very clear structure, while 
also allowing thorough discussions.
Even though the proposal will be reviewed by experts in the field, 
it should not be crammed with scientific terms (technical or clinical), 
especially when it comes to sections that are not describing the work 
plan of the project. The proposal should, as far as possible, address the 
big picture in explaining the significance of the project and its mid- and 
long-term impacts at the European level – taking into account social, 
economic and environmental considerations when possible. You might 
consider that such project outcomes are implied but they should nev-
ertheless be clearly stated for the reviewer as take-home messages to 
emphasize the project’s benefits. With his usual sense of humour, one of 
our partners suggested that the experts would not be as good as anyone 
in the team, precisely because they were not in the team.
A further valuable piece of advice is to hold a face-to-face meet-
ing as early as possible during development of the proposal. It might 
be useful to sign a confidentiality agreement among partners to ena-
ble free discussion of all aspects of the project prior to the protection 
offered by the consortium agreement. All considerations relating 
to intellectual property (e.g. ownership of results and exploitation 
rights) should be covered at the earliest possible stage to defuse any 
disagreements on these thorny topics.
5.3. Experience and advice on the submission/grant 
signing process
Submission of a project entails a significant amount of administra-
tive paperwork, and this is especially true as one moves to step 2 in 
the submission of an FP7 or (now) a Horizon 2020 programme. It is 
very advisable to identify one administrative contact person for each 
partner as early as possible during the submission phase (this is gen-
erally not a scientific expert) to facilitate and accelerate exchanges. 
This will in particular assist the coordinator in the task of collecting 
all the required administrative data.
It goes without saying (but it is nevertheless better to say it!) 
that one must be prepared in advance and anticipate technical issues 
regarding the submission platform due to an excessive number of con-
nections. Submission should take place at least a few hours before the 
deadline, and preferably on the preceding day to be on the safe side.
As regards negotiation with the European Commission, be ready 
to allow for some changes in budget. In the case of SADEL, the deci-
sion to fund one additional project with the fixed envelope that was 
allotted to the call meant that we had to reduce the programme 
budget and duration by 1/6th. There is little that can be done about 
such changes, and you need to be sufficiently flexible to keep the 
original promises, even under the altered conditions. SADEL origi-
nally planned to start a Phase I study in the sixth year, but since we 
had to reduce the duration of the project to 5 years, patient recruit-
ment is no longer planned within this framework.
With respect to the grant signing process, as soon as a project 
officer has been assigned, communication with him/her is of the 
utmost importance to ensure that the process occurs smoothly. 
This is especially important, given that online platforms from the 
European Commission are sometimes very confusing.
5.4. How to get the project started and guide it 
throughout the project phases
The kick-off meeting should be conducted face to face to immedi-
ately establish firmer links between the participants, who are due to 
work together for several years on the project. This is all the more 
important if the persons in question have never met before; the 
impact of the human dimension of a consortium on a project’s suc-
cess should not be underestimated.
For SADEL, we organize regular discussions among partners: 
every 2 months a Steering Group meeting by TC/WebEx enables all 
pertinent scientific and technical aspects to be covered. Face-to-face 
meetings are also key: every 6 months a Board of Partners meeting is 
organized to take more strategic decisions on the project’s direction. 
Each time, a partner invites the others to its facilities/city to make 
the meeting friendlier. And before a full day of discussions a relaxed, 
social dinner is organized.
It is important that contacts for each partner are clearly identified, 
comprising one person with a scientific background and one with an 
administrative background (the latter having already been identified 
before the start of the process) as well as one person – who might be 
different – who will review all communication/dissemination docu-
ments. Communication on the outcomes is an integral part of a pro-
ject and is highly recommended by the European Commission. The 
consortium agreement determines the document approval process by 
all partners, knowing that in the end it is easier to have one person 
per partner who is responsible for the approval as this will avoid an 
extended list of recipients and speed up the process.
We have also found that, even though we have had very few oppor-
tunities to meet the project officer face to face, it has been beneficial to 
put any questions to the officer. Major issues are best handled in person 
but in our case it proved very helpful to validate decisions taken during 
the course of the project and their administrative consequences.
6. Biomarkers for clinical decision-making in 
IBD, an unmet clinical need: the IBD Character 
and IBD BIOM projects
6.1. IBD Character
IBD Character is a multicentre consortium of leading academic 
and industrial SME researchers in IBD who are studying genom-
ics, epigenomics, proteomics and metagenomics in newly diagnosed, 
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treatment-naive IBD (Figure 1). A  large prospective multicentre 
cohort of 675 newly diagnosed IBD patients, symptomatic controls 
and healthy volunteers has now been recruited across five clinical 
centres in Europe.
Objectives of this project are:
•	 Development of robust biomarkers for clinical diagnostic and 
prognostic applications in IBD during early manifestations;
•	 Development of biomarkers that can stratify IBD according to 
disease progression and response to therapies;
•	 Integration of multi-omic datasets to gain a better understanding 
of disease pathogenesis;
•	 Identification of novel therapeutic targets and mechanisms of ini-
tiation of disease.
Blood, tissue and faecal samples from well-phenotyped individuals are 
currently being analysed at scientific centres across Europe using state-
of-the-art multi-omic technologies.13,14,15 Data generated from these 
analyses will provide a molecular snapshot of IBD in its early mani-
festation and early analysis has already identified novel biomarkers in 
IBD.16 Techniques to integrate these multidimensional datasets will be 
developed within the consortium. These data will provide a platform 
for novel biomarker discoveries and allow a better understanding of 
the biological processes involved in the pathogenesis of IBD.
6.2. IBD-BIOM
IBD-BIOM is a multidisciplinary consortium of leading academic 
and industrial SME researchers in IBD. A  major strength of the 
IBD-BIOM study design is early generation of data in parallel with 
prospective recruitment of newly diagnosed IBD patients. A  large 
number of high-quality, well-phenotyped biobanked patient samples 
(n > 6500) have been distributed and analysed by scientific partners 
throughout Europe. Significant progress has been made by our ana-
lytical partners, global leaders in their respective disciplines; epig-
enomic, glycomic, glycoproteomic and activomic technologies have 
been harnessed and applied to IBD research and have already yielded 
exciting early data and publications.17–20
In parallel with the ongoing scientific biomarker discovery, pro-
spective recruitment of newly diagnosed IBD patients and controls 
has now been successfully completed at clinical centres. The target 
of 1200 patients has been met and exceeded. The novel putative bio-
markers identified from the retrospective phase of the project will 
now be tested and validated in the large number of samples from 
prospectively recruited patients.
We believe that the inclusion of these complementary analyses 
will elucidate pathways through which environmental exposures 
influence IBD risk and progression and will consequently facilitate 
the development of novel early IBD diagnostics. A complex systems 
biology approach will be used to integrate, interrogate and under-
stand this multidimensional dataset in order to achieve the aims of 
identifying novel diagnostic and prognostic biomarkers as well as 
new targets for therapeutic intervention.
The objective of this project is the development of a robust bio-
marker for clinical application in the diagnosis and stratification of 
IBD patients by:
•	 Complex phenotyping of IBD patients;
•	 Stratification of patients with IBD, in terms of disease course and 
response to treatment;
•	 Integration of genomic, epigenomic, immunological, glycomic 
and activomic data;
•	 Elucidation of molecular targets for new therapies for IBD;
•	 Acquisition of insights into disease pathogenesis.
6.4. Experience and advice on proposal preparation
It is important to choose the right consortium, based on the call text 
and the project idea. Writing a project proposal is a long process 
that should not be underestimated. The consortium must start to 
work on the project as soon as possible since it takes longer to write 
an EU application than one would expect. Finally, the project parti-
tioning is also a crucial element: it has to be decided who is leading 
which work package and each person must be persuaded to write the 


















Figure 1. Planned analyses in IBD Character.
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6.5. Experience and advice on the submission/grant 
signing process
For most EU proposals the application can be submitted as often as 
one wishes up until the deadline, so do not hesitate to start this pro-
cess early. We would advise that validation of consortium members 
by the European Commission is sought as soon as possible, since fail-
ure to do so will delay signing of the grant agreement. It is advisable 
to draw up the consortium agreement immediately upon notification 
of the award as this will ease the grant preparation stage and smooth 
the next steps.
6.6. How to commence the project and obtain 
guidance throughout the project
It is necessary to arrange a kick-off meeting with all the partners 
at the very beginning of the project. If possible, the coordinator’s 
finance team should be invited to discuss the main EU financial and 
administrative procedures.
We would strongly advise that, whenever feasible, a project 
administrator/co-ordinator be appointed to liaise with the EC 
project officer and all the partners. Do not underestimate the time 
spent on administrative and financial matters, especially when these 
involve amendments to the grant agreement.
Exchange of information among the different partners is 
facilitated by regular telephone conferences involving the whole 
consortium and the various committees that have been set up. 
For instance, we judged that at least one annual face-to-face 
meeting is necessary; this will ensure good communication 
among all the members, which is essential for smooth running 
of the project.
Always follow up on action points from meetings and tel-
ephone conferences in order to submit deliverables on time 
to the EC. We would emphasize the importance of starting to 
prepare each periodic financial and scientific report as soon 
as possible and of regularly reminding the partners about 
deadlines. It is also important to keep the EU project officer 
updated. Do not hesitate to contact him/her and ask for advice 
if unsure.
7. The BIOCYCLE project
7.1. Introduction
The main aim of the BIOCYCLE project is to test and critically assess 
the benefits and risks of an innovative regimen for optimizing the 
maintenance treatment of moderate to severe Crohn’s disease. The 
current gold standard is a prolonged combination of anti-TNF-α and 
antimetabolites; the new tested regimen includes treatment cycles after 
prolonged remission has been reached. The cycles are characterized by 
periods when both drugs are administered alternating with periods 
when either anti-TNF-α or antimetabolites are withdrawn. The objec-
tive is to achieve benefits with respect to both safety and costs while 
preserving the same level of efficacy during the maintenance therapy.
The project comprises nine work packages and involves 13 part-
ners across Europe, Israel and the USA (Figure  2), representing a 
multidisciplinary consortium.
The objectives of the project are:
•	 To conduct a Phase IV, prospective, open-labelled, randomized, 
controlled, multicentre, three-arm study (SPARE) to assess de-
escalation strategies (anti-TNF-α withdrawal, antimetabolite 
withdrawal, continuation of combination therapy);
•	 To evaluate the impact of treatment cycles on the overall cost 
and cost-effectiveness of the maintenance combination therapy;
•	 To assess the acceptance versus reluctance of the patients, car-
egivers and national healthcare systems regarding the treatment 
cycle strategy;
•	 To synthesize, analyse and critically assess the data generated by 
the BIOCYCLE project for performance of a knowledge-based 
appraisal of the treatment cycle concept;
•	 To activate the most appropriate dissemination actions and com-
munication channels to accelerate the implementation of the best 
practices for managing patients with moderate to severe Crohn’s 
disease during remission periods.
The consortium will generate and collect a large number of 
clinical data (the first specific objective is to run the SPARE clinical 






























































WP2-Dissemination and Exploitation Guidelines
and Knowledge transfer to Deciders [WP-L: IBDIM]
Figure 2. BIOCYCLE at a glance.
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relating to the expectations of patients, caregivers/providers and 
healthcare systems regarding withdrawal of either anti-TNF-α or 
antimetabolites in treatment cycles, compared with combination 
therapy without interruption. A critical appraisal of the new regimen 
and its impact on overall CD management will be performed. This 
will progressively lead to recommendations and decision-making 
tools designed to appropriately optimize the maintenance therapy of 
patients with CD in accordance with their needs and characteristics.
7.2. Experience and advice regarding proposal 
preparation
The starting point is certainly a good and relevant research idea. 
Most of us are full of very bright research ideas, but a promising idea 
in itself is not sufficient. The idea has to be shared and discussed by 
a group of collaborators representing the heart of the future consor-
tium. This small group of investigators will be responsible for seeing 
the project through to its conclusion.
Writing a description of the entire project takes much time and effort. 
This task must be performed by a skilled scientist very well aware of EU 
rules concerning European project applications and, more specifically, 
concerning the specific targeted action (i.e. Horizon 2020). To be homo-
geneous and consistent, the full application should be written or at least 
intensively reviewed by a single person who has to take the lead. Ideally 
this person should be one of the members of the small starting group of 
investigators. In our experience, the assistance of a scientist who special-
izes in EU projects has a huge impact. This person can make the project 
fit perfectly with the specific call. Indeed, each sentence and even each 
word of the project description should be tailored with this in mind, and 
the project must address all specific aspects of the call. To achieve this, 
a multidisciplinary team will usually be necessary. Thus, contacts and 
discussions with researchers outside one’s own domains will be required 
and these investigators should be included in the consortium if they are 
motivated and adaptable. They will have to participate in the writing of 
specific work packages and must thus be ready to accept this workload 
without being sure that the project will be selected and funded.
Beyond the relevance and the scientific value of the project, careful 
consideration must be given to the dissemination plan and the impact of 
the project. These aspects are of paramount importance for the EU and, 
as they are beyond the scientific project itself, they are often overlooked 
by investigators. The dissemination plan must cover not only scientific 
publications but also public awareness campaigns aimed at facilitating 
implementation of the conclusions of the research project. The required 
amount of energy and brainstorming should be devoted to the question 
of impact, with analysis of the current situation regarding the question 
tackled by the project and estimation of the potential impact of dissemi-
nation and implementation of the outcomes of the project.
Overall, preparation of the project requires the investment of 
much time in assembling the multidisciplinary consortium, matur-
ing the research ideas and making them fit perfectly with the call, 
and writing the application. In addition, financial investment is usu-
ally necessary to acquire the help of skilled people who can assist 
the initial small group of investigators in writing both the admin-
istrative and the scientific part of the application. In the case of the 
BIOCYCLE project, the expenditure had to cover the costs of two 
people working almost half-time for 3–6 months.
7.3. Experience and advice regarding the 
submission/grant signing process
The large amount of administrative work and the potential difficulty 
(given the multiple partners involved) in motivating partners’ teams 
and administrative collaborators to fill in all the necessary informa-
tion can represent significant obstacles in this stage of the application 
process. A crucial advantage is gained by having, within the coordi-
nator’s team, one resource person who has perfect knowledge of all 
the tips and tricks regarding these administrative tasks and is able to 
interact effectively with EU officers to resolve any problems. Another 
very important aspect is the legal status of the entities that will be 
part of the consortium. All these entities, which are sometimes sim-
ple associations of researchers or investigators, must have legal sta-
tus in compliance with their national laws. Potential problems in this 
regard have to be identified and solved well in advance since many 
other tasks have to be done shortly before the end of the successive 
deadlines for the action. Beside the signing of the grant agreement 
between the EU and the different partners in the action, a consor-
tium agreement must also be set up. This consortium agreement sets 
out the rules governing the functioning of the consortium and is an 
important document with respect to the rights and responsibilities of 
each partner and the key issue of intellectual property. Here again, 
the help and advice of experts in the field will be important. A high 
level of mutual understanding and trust between the consortium 
members is also essential since the final consortium agreement will 
have to include the specific requests from, and obligations of, a large 
number of collaborators. In the case of the BIOCYCLE project, for 
example, 13 partners had to reach a consensus on the consortium 
agreement. Working on an EU template will facilitate the process, as 
will open discussion with the partners and flexibility on the contro-
versies that arise.
7.4. How to initiate the project and guide it through 
the project phases
The partitioning of the project into several work packages with dif-
ferent persons responsible for different packages confers a significant 
advantage and ensures that progress is likely to be made according 
to schedule. The schedule is also determined by milestones and deliv-
erables that have been clearly defined in the project.
The consortium must very carefully follow the schedule as 
well as the rules of the EU: this is essential both for realization 
of the project and for claiming the funding for the project. The 
consortium must stick perfectly to the grant agreement. It is the 
responsibility of an executive board to meet regularly (most often 
virtually) to discuss issues and make sure that the action remains 
on track. Identification of risks and implementation of a risk man-
agement plan are also very useful and are advocated by the EU. 
Here, again, the help of a dedicated person or entity capable of 
assisting the coordinator in his/her task is important. In the case of 
the BIOCYCLE project, a specialist helps the coordinator in organ-
izing executive board meetings, in requesting amendments to the 
grant agreement proposed by partners and in scientific and financial 
reporting. As the BIOCYCLE project is still in its early stages (hav-
ing been launched in April 2015), no further information on these 
aspects can currently be reported.
8. Conclusion
The success rate of eligible proposals over the first Horizon 2020 calls 
was around 14%.21 Preparing a project proposal for a Horizon 2020 call 
is a long and complex process and not all competitive projects are selected 
when they are first submitted. This article has aimed to highlight, based 
on the experience gained in several EU-funded projects, the problems that 
commonly arise during proposal writing and the criteria that must be 
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fulfilled if a proposal is to be successful. ECCO is looking forward to 
discussing these projects in greater detail during its open access EU Project 
Forum on March 16, 2016 at the ECCO’16 Congress in Amsterdam; this 
Forum will aim to facilitate exchange of knowledge and sharing of pro-
ject experience and to identify potential new synergies among senior and 
junior researchers and among basic scientists and clinicians.
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